Back to top

BTIG Reaffirms Their Buy Rating on Adaptive Biotechnologies (ADPT)

BTIG analyst Mark Massaro maintained a Buy rating on Adaptive Biotechnologies (ADPT – Research Report) today and set a price target of $6.00. The c...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Adaptive Biotechnologies Corporation (ADPT)